Servier Accelerates its Digital Transformation with Google Cloud

Paris (France), September 22, 2022 - Global pharmaceutical group Servier announced today a strategic collaboration with Google Cloud marking a new step in Servier's digital transformation. The collaboration will bring data and artificial intelligence together to increase in particular the therapeutic innovation capacities of the Group to serve patient needs.

For Virginie Dominguez, Servier’s Executive Vice-President Digital, Data and Information Systems: “Combining scientific innovation with the power of technology will enable significant progress in overall patient engagement. Data and artificial intelligence are opening up tremendous prospects for drug discovery, disease prevention, and improved treatment adherence across the entire pharmaceutical value chain. We were looking for a strategic partner to assist us with these technologies. We have selected Google Cloud for its knowledge of the health sector, its power to innovate, and its commitment to cloud services that are compliant with GDPR\(^1\) and stringent digital sovereignty requirements.”

Under the terms of this partnership, Google Cloud will support Servier in its migration to the cloud and provide the Group with innovative tools offering augmented computing power and the possibility to accelerate the analysis and understanding of data thanks to artificial intelligence.

Anthony Cirot, Google Cloud France country manager: “Our extensive and ambitious collaboration with Servier is the epitome of our approach with our customers: supporting French organizations’ innovation and growth, with relevant skills and solutions, including local support and a commitment to working closely with the teams, all with the highest security and confidentiality levels.”

Google Cloud technology will benefit all areas of the company, from research, to production to distribution. In R&D, for example, it will facilitate the work of Servier researchers who are using increasingly sophisticated algorithms to accelerate the discovery and provisioning of new therapeutic solutions. Trained on vast quantities of anonymised data, these algorithms generate models that facilitate the identification of molecules of interest and therapeutic targets, increasing the probability of success during clinical phases. The solutions will also help Servier to optimize its production and distribution chain, thereby reinforcing the continued supply of treatments and preventing stock shortages that constitute a public health problem for patients and healthcare professionals.

By collaborating with Google Cloud and its ecosystem of partners, Servier envisages the co-construction of innovative initiatives, such as the use of artificial intelligence to accelerate the development of new therapies.

\(^1\) The General Data Protection Regulation
drugs, or the advanced analysis of real-world data to provide new scientific evidence of drug efficacy and tolerability.

In order to reinforce the competencies of the teams in the domain of digital technologies, Servier has also developed advanced training and acculturation programs for all its employees worldwide. Google Cloud, associated with this program, will provide training on data and artificial intelligence technologies, thereby fostering the teams’ transition to a data-driven culture.

---

About Servier

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient's voice at the heart of its activities.

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.

More information: www.servier.com

Follow us on social media: LinkedIn, Facebook, Twitter, Instagram

Press contact:
Sonia Marques
presse@servier.com
Tel: +33 (0)1 55 72 40 21